Immunize.org supports evidence-based vaccination recommendations and schedules. Read more at About Us.

Ask the Experts: RSV (Respiratory Syncytial Virus): Vaccine Recommendations for Adults

Results (4)

The American Academy of Family Physicians (AAFP) and CDC both recommend one RSV vaccine dose for previously unvaccinated adults age 75 and older and adults age 50–74 at increased risk. Neither routinely recommends adult vaccination below age 50.

AAFP’s current 2026–27 RSV guidance incorporates the American College of Obstetricians and Gynecologists (ACOG) recommendation for a longer window for offering maternal vaccination during pregnancy (September 1–March 1, compared with CDC’s recommended September 1–January 31). AAFP also endorses the American Academy of Pediatrics (AAP) expanded recommendations for the categories of high-risk children eligible for nirsevimab protection before or during their second RSV season. See AAFP’s guidance at www.aafp.org/assets/image/upload/v1791920857/pdf_2026_through_2027_rsv_guidance.pdf. AAFP’s September 2026 adult respiratory immunization guidance is available at  www.aafp.org/assets/image/upload/v1788277985/pdf_2026_through_2027_influenza_rsv_sars_covid_2_guidance.pdf.

Last reviewed: November 8, 2026

CDC specifies for RSV vaccination the same moderate to severe immunocompromising conditions that require additional doses of COVID-19 vaccines. Below is the CDC description from its website (www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html#cdc_cg_special_populations_section_3-description-of-moderate-and-severe-immunocompromising-conditions-and-treatment).

Moderate and severe immunocompromising conditions and treatments include but are not limited to:

  • Active treatment for solid tumor and hematologic malignancies
  • Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)
  • Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy
  • Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy)
  • Moderate or severe primary immunodeficiency (such as common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, or Wiskott-Aldrich syndrome)
  • Advanced HIV infection (people with HIV and CD4 cell counts less than 200 per cubic milliliter, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection
  • Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.

For additional information about the degree of immune suppression associated with different medical conditions and treatments, refer to the CDC General Best Practice Guidelines for Immunizations section on altered immunocompetence (www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html) and the Infectious Diseases Society of America (IDSA) issued guidance for RSV vaccination in immunocompromised patients in September 2026 (www.idsociety.org/practice-guideline/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/). In addition to the conditions listed above, IDSA offers specific clinical considerations for coordinating the timing of vaccination with transplantation, chemotherapy, B-cell-depleting treatment, and community RSV activity.

Last reviewed: November 8, 2026

No. The American Academy of Family Physicians (AAFP) and CDC recommend a single dose of RSV vaccine for eligible adults. Revaccination after the single dose is not recommended at this time. Available evidence shows some protection persists through two or three seasons, although protection wanes over time.

For pregnant individuals who were vaccinated during a previous pregnancy, the infant should receive an RSV preventive antibody for protection during their first RSV season.

Last reviewed: November 8, 2026

The Infectious Diseases Society of America (IDSA) recommends RSV vaccination for immunocompromised adults beginning at age 18. IDSA’s guidance document also expressed support for case-by-case consideration of vaccination of immunocompromised children younger than age 18 years; however, use in nonpregnant people younger than 18 is not an FDA-approved indication, nor is it recommended by the American Academy of Pediatrics (AAP). In contrast, CDC’s risk-based adult recommendation begins at age 50, with routine vaccination of all adults age 75 and older.

IDSA generally recommends one dose, consistent with the FDA and other recommending bodies. IDSA guidance allows for a treating clinician to consider additional doses for an immunocompromised patient on an individual basis, such as when vaccination occurred before optimal immune recovery. CDC and other medical societies do not currently recommend off-label routine revaccination. IDSA provides specific recommended considerations for coordinating timing of vaccination with transplantation, chemotherapy, B-cell-depleting treatment, and when to act before or during periods of elevated RSV activity in the patient’s community. See www.idsociety.org/practice-guideline/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/.

Last reviewed: November 8, 2026

This page was updated on .